Hua Bao
About Hua Bao
Hua Bao, Vice President, Research & Development
Hua Bao holds the position of Vice President, Research & Development. In this role, Hua Bao is involved in the innovative development of clinical research tools and methodologies. This encompasses leading scientific teams and projects aimed at advancing medical knowledge and treatment approaches. Notably, Hua Bao’s efforts in R&D have contributed to significant advancements in the field of oncology.
Hua Bao's Study on Circulating-Free DNA Fragmentomics
Hua Bao authored a pivotal study focused on the clinical use of circulating-free DNA fragmentomic for monitoring minimal residual disease in patients with non-small-cell lung cancer. This study explores the potential of fragmentomics in detecting and managing residual cancer cells post-treatment. The findings present important implications for improving patient outcomes through more precise and early detection methods.
Development of Regularized Cox Regression Models by Hua Bao
Hua Bao developed regularized Cox regression models to identify high-risk patients post-surgery. These models utilize whole-genome sequencing-based cell-free DNA fragment profiles to enhance the prediction of patient outcomes. This development represents a significant advancement in post-surgical monitoring and risk assessment, providing a more data-driven approach to patient care.
Detection Sensitivity in Recurrence Monitoring by Hua Bao
Hua Bao achieved a detection sensitivity of 78.3% for patients with recurrence using combined fragmentomics and circulating mutation results. This high level of sensitivity underscores the effectiveness of integrating fragmentomic analysis with mutation detection, offering a powerful tool for early recurrence monitoring and potentially improving long-term patient prognosis.